Heterogeneity of immune checkpoint inhibitor-related inflammatory central nervous system adverse event reporting signals in primary and metastatic brain tumors: a pharmacovigilance study with single-cell and spatial transcriptomic contextualization

• by Junlin Song, Zeyu He, Chong Han, Xiaohong Hou

• July 8, 2026

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

• by Luca Paruzzo, Emeline R. Chong, Elise A. Chong, Zhixuan Zheng, Puneeth Guruprasad, Daniel J. Landsburg, Sunita D. Nasta, Federico Stella, Ranjani Ramasubramanian, Vitor B. de Souza, Mohannad H. Alkhatib, Matthew Ho, Antonio Imparato, Gregory M. Chen, Don L. Siegel, Gabriela Plesa, Anlan Dai, Shane Mackey, Priyamvada Das, Peter Michener, Julie Jadlowsky, Frederic D. Bushman, Vrutti Patel, Alberto Carturan, Ellen B. Napier, Vanessa E. Gonzalez, Danuta Jarocha, Rong Xu, Bruce L. Levine, Patrizia Porazzi, Noelle Frey, David L. Porter, Jakub Svoboda, Joseph A. Fraietta, Carl H. June, Stephen J. Schuster, Marco Ruella

• August 26, 2026

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

• by Trang Thuy Do, Jordan Maccora, Rebecca Wallace, Veronica Aedo-Lopez, Marliese Alexander, Sonia Ancoli-Israel, Bei Bei, Robert Blum, Frances Boyle, Daphne Day, Justine Diggens, Prudence A. Francis, Maria Ftanou, Sheila N. Garland, Alysia Kepert, Duncan Mortimer, Andrew J. K. Phillips, Sharad Sharma, Lesley Stafford, Michelle White, Joshua F. Wiley

• August 27, 2026

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

• by

• August 26, 2026

• 5 min